Market research: check. IP strategy: check. Welcome to the ‘valley of death’ – the lethal gap between innovation and income, haunted by failed entrepreneurs.
Due to net negative cash flow, 50% of businesses fail in their first year and 80% in the first five years. Why? Because as Ben Franklin said ‘If you fail to plan, you are planning to fail.’
Your best plan might be to sell or license your IP. Perhaps you should commercialise your IP within an existing entity, create a spin-off, or establish a start-up. Alternatively, your brightest future may lie in a merger or acquisition, or a joint venture.
gemaker can help you plan your route out of the deadly valley and choose the right commercialisation vehicle to transport you safely onto the upward slope of business growth.
Contact gemaker to discuss your commercialisation strategy needs and receive a quote.
Related Success Stories
Related Insights
Trailblazer Universities Program
This week the Federal Government announced investment in a new program to support improved commercialisation outcomes from University-based research offering $242.7m over 4 years. Key Highlights Four competitively selected universities will each be awarded $50m over 4...
gemaker’s submission for The Higher Education Research Commercialisation IP Framework
This is gemaker's response to Australian Government's consultation paper on The Higher Education Research Commercialisation IP Framework, released on 20 September 2021 Our Feedback We congratulate the Australian Government for focusing attention on the vital tech...
A 10-year-old gem that helps others to shine
Gems, in fact, are a species of mineral flowers; they are the blossoms of the dark, hard mine; and what they want in perfume, they make up in durabilityHarriet Beecher Stowe Growing gemaker since 2011 has involved some dark days and lots of hard work for me and my...
Not All Heroes Wear Capes
Meet the chemistry superheroes fast-tracking innovation, showcasing Australian technology to the world. If you could create a perfect company during a global pandemic, it would look a lot like EpiChem, a wholly owned subsidiary of PharmAust (ASX:PAA). “We’re all about...
SCOPR survey only tells part of the research commercialisation story
This week, Knowledge Commercialisation Australasia released its first Survey of Commercial Outcomes from Public Research (SCOPR). Based on data collected and analysed by gemaker from 34 Australian and 15 New Zealand universities and research organisations, SCOPR...
Niamh Chapman – That’s what I call Science
To celebrate International Women's Day and as part of our commitment to being Women in STEM Decadal Plan Champions, we're highlighting an impressive early career researcher who is definitely on the rise. Niamh Chapman is a passionate medical research and science...